AMRX News and Press, Amneal Pharmaceuticals Inc. Class A

2024-07-29 17:07:57 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success Amneal Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript ...

First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...

2024-07-12 12:35:09 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Teva Pharmaceutical: Buy This Bargain Before It's Gone Teva Pharmaceutical Industries Limited (TEVA) B...

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...

2024-07-10 11:40:54 ET Summary Amneal Pharmaceuticals has seen a significant increase in its share price of >400% after hitting an all-time low in March 2023. The company reported record revenues in Q1 2024, with growth in all three reportable segments - Generics, Specialty, an...

FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...

2024-07-01 10:22:31 ET More on Teva Pharmaceutical Teva Pharmaceutical: Buy This Bargain Before It's Gone Teva to pay $750M as part of tax deal with Israel Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcrip...

Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO ® & FYLNETRA ® ) ADL018 is Kashiv’s lead pipeline biosimilar program, currently in Phase III Kashiv BioSciences, LLC (“Kashiv” or the “Companyȁ...

Builds on U.S. biosimilar portfolio of seven products with three commercial and four in pipeline 8 th biosimilar expands portfolio into allergy treatments, a new therapeutic area Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Companyȁ...

Fourth ESG Report Details Company’s Progress Towards Environmental Sustainability and Contributions Toward Building Healthier Communities as a Leading Provider of Accessible Medicines Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Companyȁ...